TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23709583

Group type: EXPERIMENTAL
Intervention: Telemonitoring and supervision by usual primary care clinicians of home self measured blood pressure with optional patient decision support for six months
Number of subjects: 401

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention
Number of subjects: 401
Study: 22204448

Group type: EXPERIMENTAL
Intervention: Systematic pediatric care between the 7th and 28th day of life
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (live-born infants with CL/P between 2001 and 2002)
Number of subjects: 47
Study: 19704066

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg/mo (plus 500 mg on day 14 of month 1)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Anastrozole 1 mg/d
Number of subjects: 205
Study: 17273013

Group type: EXPERIMENTAL
Intervention: Lavender essential oil for inhalation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Inert oil (placebo) for inhalation
Number of subjects: 118
Study: 15064923

Group type: EXPERIMENTAL
Intervention: Dynamic patellofemoral brace (On‐Track System, dj Orthopedics) worn during all physical activities for 6 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no brace) following the same 6-week training program
Number of subjects: 167
Study: 11349180

Group type: EXPERIMENTAL
Intervention: Intracervical placement of laminaria
Number of subjects: 50

Group type: COMPARATOR
Intervention: Extra-amniotic saline solution infusion
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 9159448

Group type: EXPERIMENTAL
Intervention: PR-A and PR-B immunohistochemistry
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Western blotting
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RNase protection assay
Number of subjects: 11
Study: 8265095

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: 32 mg ondansetron
Number of subjects: 496

Group type: COMPARATOR
Intervention: 3 mg granisetron
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 496
Study: 3663434

Group type: EXPERIMENTAL
Intervention: Meptazinol 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meptazinol 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meptazinol 48 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pethidine 20 mg
Number of subjects: 0
Study: 29652755

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment and rehabilitation program including preop chemotherapy, surgery, postop rehabilitation, and mesodiencephalic modulation (MDM) sessions after each invasive intervention.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (details of intervention not specified).
Number of subjects: 21
Study: 26481656

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 115
Study: 25485879

Group type: EXPERIMENTAL
Intervention: Intraoperative dexmedetomidine (1 μg kg(‐1) loading dose followed by 0.5 μg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 109
Study: 22922682

Group type: COMPARATOR
Intervention: Ticagrelor (loading dose 270 mg; 90 mg twice daily for 7 days) plus atorvastatin (80 mg on day 5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ticagrelor (loading dose 270 mg; 180 mg twice daily for 7 days) plus simvastatin (80 mg on day 5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ticagrelor with atorvastatin metabolites
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ticagrelor with simvastatin acid
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ticagrelor (single dose)
Number of subjects: 48
Study: 22029963

Group type: EXPERIMENTAL
Intervention: MTRX1011A at 1.5 mg/kg subcutaneously (s.c.) weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTRX1011A at 3.5 mg/kg s.c. weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MTRX1011A at 5 mg/kg intravenously (i.v.) weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTRX1011A (various doses)
Number of subjects: 0
Study: 19103694

Group type: EXPERIMENTAL
Intervention: Andalusian Advance Directive Form (AADF)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Informative and deliberative sessions about end-of-life decision making
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 171
Study: 17026510

Group type: EXPERIMENTAL
Intervention: Repeated professional tooth cleaning combined with oral hygiene instruction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral hygiene instruction only (Control)
Number of subjects: 12
Study: 14629059

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ropivacaine (higher dose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Local anesthetic infiltration
Number of subjects: 15
Study: 10930965

Group type: EXPERIMENTAL
Intervention: Final pharmacostatistical model for lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enzyme-inducing antiepileptic drugs without valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight as a covariate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sex effect on clearance
Number of subjects: 0
Study: 7642042

Group type: EXPERIMENTAL
Intervention: i.v. atenolol
Number of subjects: 12377

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 12377

Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 12377

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 12377
Study: 2504972

Group type: EXPERIMENTAL
Intervention: Mifurol (6-12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tegafur (12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Number of subjects: 0
Study: 969779

Group type: EXPERIMENTAL
Intervention: Choleretics administered orally in a dosage two to five times more than the recommended one
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized secretion‐stimulation (dehydrocholic acid, i.v., taurocholic acid intraduodenally, secretin i.v., meals)
Number of subjects: 0
Study: 31725115

Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 12018

Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 12018
Study: 30422319

Group type: EXPERIMENTAL
Intervention: Rolapitant with midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rolapitant with ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rolapitant with rifampin
Number of subjects: 0
Study: 28234235

Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (PI‐mono)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 16
Study: 26136404

Group type: EXPERIMENTAL
Intervention: Families Taking Control (FTC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Delayed Intervention Control (DIC)
Number of subjects: 83
Study: 25065540

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Chest Physical Therapy (CPT)
Number of subjects: 24
Study: 22791766

Group type: EXPERIMENTAL
Intervention: Concurrent PTH(1-84) and ibandronate for 6 months followed by 18 months of ibandronate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sequential PTH(1-84) for two courses of 3 months followed by 9 months of ibandronate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Concurrent PTH(1-84) and ibandronate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sequential PTH(1-84)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Concurrent and sequential therapies
Number of subjects: 44
Study: 19354091

Group type: EXPERIMENTAL
Intervention: Functional Restoration (FR) treatment group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard anesthesia pain clinic treatment comparison group
Number of subjects: 66
Study: 17586184

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 15642679

Group type: EXPERIMENTAL
Intervention: Intermittent hypobaric hypoxia (IHH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 15463835

Group type: EXPERIMENTAL
Intervention: Tobramycin nebuliser solution (TNS)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Nebulised colistin
Number of subjects: 115
Study: 9818296

Group type: EXPERIMENTAL
Intervention: Acenocoumarol once daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acenocoumarol twice daily
Number of subjects: 12
Study: 8950783

Group type: EXPERIMENTAL
Intervention: 150 micrograms recombinant human (rh) IL‐6
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control study)
Number of subjects: 8
Study: 1827042

Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: isosorbide‐5‐mononitrate (ISMN) 20 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 86
Study: 7136568

Group type: EXPERIMENTAL
Intervention: Forearm immobilization in pronation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Forearm immobilization in supination
Number of subjects: 42
Study: 30646822

Group type: EXPERIMENTAL
Intervention: Genetically instrumented T2D
Number of subjects: 318664

Group type: COMPARATOR
Intervention: Genetically determined hypertension
Number of subjects: 318664

Group type: COMPARATOR
Intervention: Elevated systolic BP or diastolic BP
Number of subjects: 318664

Group type: COMPARATOR
Intervention: Hypertension→T2D relation
Number of subjects: 318664

Group type: EXPERIMENTAL
Intervention: T2D→hypertension relation
Number of subjects: 318664
Study: 28240765

Group type: EXPERIMENTAL
Intervention: MRD <0.1% after first induction course
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MRD 0.1-1% after first induction course
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MRD >/=1% after first induction course
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MRD >/=0.1% after first induction course, followed by MRD <0.1% after second induction course
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: MRD >/=0.1% after first induction course, persisting MRD >/=0.1% after second induction course
Number of subjects: 142
Study: 25828636

Group type: EXPERIMENTAL
Intervention: Test formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Number of subjects: 24
Study: 24755244

Group type: EXPERIMENTAL
Intervention: Negative pressure drainage (group B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No drainage (group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Negative pressure drainage (group B) and 4 h clamping drainage (group C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 18
Study: 21175274

Group type: EXPERIMENTAL
Intervention: Patient-led titration of insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-led titration of insulin glargine
Number of subjects: 0
Study: 19362705

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 39
Study: 17804843

Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg twice daily
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237
Study: 15108766

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Tacrolimus (FK506)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Banff acute rejection (AR) grade >= 1A
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Clinical AR prior to day 50 biopsy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Increased tubulointerstitial CD68-positive cells
Number of subjects: 63
Study: 11411908

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 72

Group type: COMPARATOR
Intervention: UVAB phototherapy
Number of subjects: 72
Study: 9749453

Group type: EXPERIMENTAL
Intervention: Non-parametric covariance analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical model for postulated sampling process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-parametric methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted least squares application
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical model for dichotomous or ordered categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative methods for covariance analysis
Number of subjects: 0
Study: 7631727

Group type: EXPERIMENTAL
Intervention: Elective low-forceps delivery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous delivery
Number of subjects: 50
Study: 2604532

Group type: EXPERIMENTAL
Intervention: Classical Tetracoq vaccine
Number of subjects: 249

Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccines prepared on monkey kidney cells
Number of subjects: 249

Group type: COMPARATOR
Intervention: Inactivated poliomyelitis vaccines prepared on Vero-type continuous cell lines
Number of subjects: 249

Group type: COMPARATOR
Intervention: Polio vaccine placed in a 2-compartment syringe separating the polio vaccine from the DPT
Number of subjects: 249
Study: 1234488

Group type: EXPERIMENTAL
Intervention: Codeine phosphate syrup, B.P.C.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Syrup alone
Number of subjects: 6
Study: 31448116

Group type: EXPERIMENTAL
Intervention: SFA (saturated fatty acids)
Number of subjects: 27

Group type: COMPARATOR
Intervention: n-6 PUFA (polyunsaturated fatty acids)
Number of subjects: 27
Study: 28162906

Group type: EXPERIMENTAL
Intervention: Biliary stent placement with iodine-125 (125I) seeds (group A)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Biliary stent only (group B)
Number of subjects: 55
Study: 26576178

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus Zn sulfate (50 mg elemental Zn three times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 30
Study: 24266299

Group type: EXPERIMENTAL
Intervention: Holdex tube holder
Number of subjects: 60

Group type: COMPARATOR
Intervention: BD Vacutainer One Use Holder
Number of subjects: 60
Study: 21410733

Group type: EXPERIMENTAL
Intervention: AZD1386 30 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AZD1386 95 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18820505

Group type: EXPERIMENTAL
Intervention: Three-session curriculum emphasizing LC critical decisions and error prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 17217713

Group type: EXPERIMENTAL
Intervention: Xuezhikang 0.6 g Bid
Number of subjects: 4870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4870
Study: 14633563

Group type: EXPERIMENTAL
Intervention: 20 mL dilute solution (0.1%/0.5 microg/mL ropivacaine/fentanyl)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 8 mL concentrated solution
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 12 mL ropivacaine and 6 microg fentanyl
Number of subjects: 150
Study: 11084114

Group type: EXPERIMENTAL
Intervention: Ventricular resynchronization therapy (VRT) by left or biventricular stimulation
Number of subjects: 64
Study: 9084896

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine and Maprotiline
Number of subjects: 0
Study: 8409177

Group type: EXPERIMENTAL
Intervention: Terodiline
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 3548983

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 30
Study: 31308644

Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention in physical therapy (BMPI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 105
Study: 30261738

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sputum AFB smear
Number of subjects: 90
Study: 27769710

Group type: COMPARATOR
Intervention: 8-oxo-2′-deoxyguanosine (8-oxo-dG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: (5′S)-8,5′-cyclo-2′-deoxyadenosine (S-cdA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-iso-prostaglandin F2α (8-iso-PGF2α)
Number of subjects: 0

Group type: COMPARATOR
Intervention: (5′R)-8,5′-cyclo-2′-deoxyadenosine (R-cdA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 0
Study: 25415733

Group type: COMPARATOR
Intervention: Regular dose (CTDIvol, 38.4 mGy)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Reduced dose (CTDIvol, 24.6 mGy) with 30% ASIR
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Reduced dose (CTDIvol, 15.4 mGy) with 50% ASIR
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Increased ASIR percentages (70% and 90%)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: All ASIR percentages regardless of radiation dose
Number of subjects: 37
Study: 22805387

Group type: EXPERIMENTAL
Intervention: Cefotaxime/heparin lock
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard heparin lock
Number of subjects: 82
Study: 20803153

Group type: EXPERIMENTAL
Intervention: Respiratory warm-up (RWU)
Number of subjects: 9
Study: 19124398

Group type: EXPERIMENTAL
Intervention: Olmesartan (20-40 mg/day)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 165
Study: 16380885

Group type: EXPERIMENTAL
Intervention: Power Refractor (neutral)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Power Refractor (cyclo)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RK-5 (Canon)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Retinomax K-plus (Nikon)
Number of subjects: 150
Study: 12087569

Group type: EXPERIMENTAL
Intervention: Once-weekly epoetin beta (n = 84)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Thrice-weekly epoetin beta (n = 89)
Number of subjects: 173
Study: 9451066

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (1 x 10(6) kallikrein activation units)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7753541

Group type: EXPERIMENTAL
Intervention: Primary (<24 h) reamed nailing of femur shaft fracture in multiple trauma patients with thoracic trauma
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Femoral reaming
Number of subjects: 766

Group type: COMPARATOR
Intervention: Unreamed femur nailing
Number of subjects: 766
Study: 2527473

Group type: EXPERIMENTAL
Intervention: Propranolol (150 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31943297

Group type: EXPERIMENTAL
Intervention: PegIFNÎ± treatment for 48 weeks plus 24 weeks follow-up
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Polygenic score (PGS) integrating CFB rs12614 and STAT4 rs7574865
Number of subjects: 1623

Group type: COMPARATOR
Intervention: NUCs treatment for 104 weeks
Number of subjects: 1623
Study: 29273897

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 161

Group type: COMPARATOR
Intervention: Self-monitoring of capillary blood glucose (control)
Number of subjects: 161
Study: 28167468

Group type: EXPERIMENTAL
Intervention: Early intravenous nutrition therapy (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Late parenteral nutrition (Group B)
Number of subjects: 80
Study: 25655828

Group type: EXPERIMENTAL
Intervention: Active TENS device (TANYX®) applied at 85 Hz frequency for 30 minutes at eight-hour intervals for up to seven days.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device (placebo group).
Number of subjects: 40
Study: 23672269

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily at bedtime (qhs)
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 21159785

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (3.0 g eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) at a 5:1 ratio)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 18224442

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily plus omeprazole 20 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily plus placebo
Number of subjects: 70
Study: 17068673

Group type: EXPERIMENTAL
Intervention: Fetal vibroacoustic stimulation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no fetal stimulation)
Number of subjects: 72
Study: 12643886

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 682

Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Nifedipine
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 682
Study: 10676687

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.1 mg b.i.d. (initial dose), increased weekly to 0.2 mg and 0.3 mg b.i.d. as target doses.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.1, 0.2, or 0.3 mg b.i.d.)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Moxonidine and placebo
Number of subjects: 97
Study: 9511686

Group type: EXPERIMENTAL
Intervention: Antenatal group sessions on position and attachment of the baby on the breast conducted by a lactation consultant
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no antenatal teaching session)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Antenatal group sessions on position and attachment of the baby on the breast
Number of subjects: 70
Study: 8452172

Group type: EXPERIMENTAL
Intervention: Oral fleroxacin, 400 mg once a day for 4-21 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (AMX/CP), 400 mg/125 mg three times a day for 4-21 days
Number of subjects: 113
Study: 3762243

Group type: EXPERIMENTAL
Intervention: Fee-for-service plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: HMO plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMO and fee-for-service plans
Number of subjects: 0